Director/PDMR Shareholding

HALEON

17/06/2025 10:00

RNS Number : 1748N

Haleon PLC

17 June 2025

 

 

​Haleon plc: Director/PDMR Shareholding 

​ 

​17 June 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of a Transaction by a Person Discharging Managerial Responsibilities ("PDMR").

 

On 13 June 2025, the Company was notified of the following transaction as detailed below.

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Marie-Anne Aymerich
2
Reason for the notification
a)
Position/status
Independent Non-Executive Director - PDMR
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Haleon plc
b)
LEI
549300PSB3WWEODCUP19
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of £0.01 each
GB00BMX86B70
b)
Nature of the transaction
Acquisition of Ordinary Shares as a result of dividend reinvestment
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£4.07
320
d)
Aggregated information
N/A
- Aggregated volume
- Price
e)
Date of the transaction
12 June 2025
f)
Place of the transaction
London Stock Exchange (XLON)

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHGIGDLRXBDGUR